[go: up one dir, main page]

PE20090302A1 - Anticuerpo multiespecifico - Google Patents

Anticuerpo multiespecifico

Info

Publication number
PE20090302A1
PE20090302A1 PE2008000664A PE2008000664A PE20090302A1 PE 20090302 A1 PE20090302 A1 PE 20090302A1 PE 2008000664 A PE2008000664 A PE 2008000664A PE 2008000664 A PE2008000664 A PE 2008000664A PE 20090302 A1 PE20090302 A1 PE 20090302A1
Authority
PE
Peru
Prior art keywords
gro
antibody
seq
referred
specific antibody
Prior art date
Application number
PE2008000664A
Other languages
English (en)
Inventor
Stephanie Jane Clegg
Eric Dobrzynski
Jonathan H Ellis
Volker Germaschewski
Alexis Paul Godillot
Zdenka Luzmila Jonak
Alan P Lewis
John R White
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20090302A1 publication Critical patent/PE20090302A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)

Abstract

REFERIDA A UN ANTICUERPO QUE TIENE ESPECIFICIDAD MULTIPLE POR LAS PROTEINAS IL-8 HUMANA, Gro-ALFA, Gro-BETA, Gro-GAMMA Y ENA-78, DONDE DICHO ANTICUERPO COMPRENDE REGIONES VARIABLES DE CADENA PESADA Y LIGERA CODIFICADAS POR SECUENCIAS DE NUCLEOTIDOS QUE COMPRENDEN LAS SECUENCIAS DE LA SEC ID N‘:1 Y LA SEC ID N‘:3 O MODIFICACIONES DE SECUENCIAS CONSERVATIVAS DE LAS MISMAS. TAMBIEN ESTA REFERIDA A UN HIBRIDOMA O TRANSFECTOMA, UN VECTOR DE EXPRESION Y A UN PROCEDIMIENTO DE PREPARACION. DICHO ANTICUERPO ES UTIL EN EL TRATAMIENTO DE OSTEOARTRITIS, ARTRITIS REUMATOIDE, ARTRITIS EROSIVA, ENTRE OTRAS
PE2008000664A 2007-04-17 2008-04-16 Anticuerpo multiespecifico PE20090302A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91222907P 2007-04-17 2007-04-17
US4413208P 2008-04-11 2008-04-11

Publications (1)

Publication Number Publication Date
PE20090302A1 true PE20090302A1 (es) 2009-04-03

Family

ID=39872910

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000664A PE20090302A1 (es) 2007-04-17 2008-04-16 Anticuerpo multiespecifico

Country Status (29)

Country Link
US (3) US20080262203A1 (es)
EP (1) EP2146745B1 (es)
JP (1) JP5441885B2 (es)
KR (1) KR101560841B1 (es)
CN (1) CN101687035B (es)
AU (1) AU2008243049B2 (es)
BR (1) BRPI0810250A8 (es)
CA (1) CA2684626C (es)
CL (1) CL2008001071A1 (es)
CO (1) CO6251323A2 (es)
CR (1) CR11116A (es)
CY (1) CY1116671T1 (es)
DK (1) DK2146745T3 (es)
DO (1) DOP2009000236A (es)
EA (1) EA024621B1 (es)
ES (1) ES2547475T3 (es)
HR (1) HRP20150937T1 (es)
HU (1) HUE027584T2 (es)
IL (1) IL201440A (es)
MA (1) MA31310B1 (es)
MX (1) MX2009011153A (es)
MY (1) MY150525A (es)
NZ (1) NZ580239A (es)
PE (1) PE20090302A1 (es)
PL (1) PL2146745T3 (es)
PT (1) PT2146745E (es)
SI (1) SI2146745T1 (es)
TW (1) TWI473815B (es)
WO (1) WO2008130969A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
SI2202245T1 (sl) 2007-09-26 2016-10-28 Chugai Seiyaku Kabushiki Kaisha Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
ES2978400T3 (es) 2008-04-11 2024-09-11 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno capaz de unirse repetidamente a dos o más moléculas de antígeno
JP6018917B2 (ja) * 2009-12-07 2016-11-02 デシミューン セラピューティクス，インコーポレイテッド 抗炎症抗体およびその使用
CA2789416A1 (en) * 2010-02-09 2011-08-18 Glaxosmithkline Llc Novel uses
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US9605058B2 (en) 2012-05-01 2017-03-28 Glaxosmithkline Llc Antibodies against the CXC-ELR family of chemokines
EP2889376A4 (en) 2012-08-24 2016-11-02 Chugai Pharmaceutical Co Ltd ANTIBODIES Fc SPECIFIC TO FCTRII OF MOUSE
US10919953B2 (en) 2012-08-24 2021-02-16 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific Fc region variant
EP2970445A4 (en) 2013-03-12 2017-02-22 Decimmune Therapeutics Inc. Humanized anti-n2 antibodies
JO3580B1 (ar) * 2013-03-15 2020-07-05 Lilly Co Eli أجسام مضادة لكيموكين elr+ cxc شامل
US9290570B2 (en) 2013-03-15 2016-03-22 Eli Lilly And Company Pan-ELR+ CXC Chemokine Antibodies
KR20210130260A (ko) 2013-04-02 2021-10-29 추가이 세이야쿠 가부시키가이샤 Ｆｃ영역 개변체
EP2796875B8 (en) * 2013-04-23 2020-11-25 Albert-Ludwigs-Universität Freiburg Inhibitors of proteins specific for the secretome of a chondrocyte for use in the treatment of breast cancer metastasis
EP2997042B1 (en) * 2013-05-17 2019-08-07 Centre National de la Recherche Scientifique (CNRS) Anti-cxcl1, cxcl7 and cxcl8 antibodies and their applications
EP4600372A3 (en) 2014-12-19 2025-11-19 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
TW202446796A (zh) 2015-02-05 2024-12-01 日商中外製藥股份有限公司 包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2019036605A2 (en) * 2017-08-17 2019-02-21 Massachusetts Institute Of Technology MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
EP4116327A1 (en) 2017-10-11 2023-01-11 Board Of Regents, The University Of Texas System Human pd-l1 antibodies and methods of use therefor
TWI827585B (zh) 2018-03-15 2024-01-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
EP3768298A4 (en) 2018-03-23 2021-12-08 Board of Regents, The University of Texas System HUMAN ANTI-PD-L2 ANTIBODIES AND PROCESSES FOR USE
CN112105644B (zh) * 2018-03-23 2023-12-05 得克萨斯州大学系统董事会 针对人pd-l1和pd-l2的双重特异性抗体及其使用方法
EP4501355A3 (en) 2018-03-23 2025-04-30 Board Of Regents, The University Of Texas System Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
TWI884192B (zh) * 2019-12-05 2025-05-21 美商西健公司 抗αＶβ６抗體及抗體-藥物結合物
TW202206457A (zh) * 2020-04-24 2022-02-16 美商美國禮來大藥廠 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體
US20220080044A1 (en) * 2020-09-14 2022-03-17 National Yang-Ming University Method for preventing or treating peripheral arterial occlusive disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE913192A1 (en) 1990-09-12 1992-02-25 Scripps Research Inst Active site of interleukin-8: polypeptide analogs and¹antibodies
US6448379B1 (en) * 1993-09-14 2002-09-10 Chiron Corporation IL8 inhibitors
JP4423680B2 (ja) * 1995-06-07 2010-03-03 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Ｃｄｒ−グラフト化抗組織因子抗体及びその使用
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
AR030753A1 (es) * 2000-09-25 2003-09-03 Smithkline Beecham Corp Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas
MXPA03003144A (es) * 2000-10-13 2004-12-06 Biogen Inc Anticuerpos humanizados anti-lt-??-r.
JP4318458B2 (ja) 2001-04-26 2009-08-26 ダコ デンマーク アクティーゼルスカブ ｐａｎ特異的モノクローナル抗体
US20040022726A1 (en) * 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
CA2510087C (en) * 2002-12-16 2018-09-04 Medarex, Inc. Human monoclonal antibodies against interleukin 8 (il-8)
AU2003303543A1 (en) * 2002-12-26 2004-07-29 Chugai Seiyaku Kabushiki Kaisha Agonist antibody against heteroreceptor
WO2005094882A1 (en) * 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
MX2007015010A (es) * 2005-06-02 2008-03-14 Astrazeneca Ab Anticuerpos dirigidos a cd20 y usos de los mismos.
CN101500597A (zh) * 2005-06-17 2009-08-05 伊姆克罗尼系统公司 治疗转移性骨癌的受体拮抗剂
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
US20070161089A1 (en) * 2005-11-08 2007-07-12 Genentech, Inc. Method of Producing Pan-Specific Antibodies
US8454960B2 (en) * 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains

Also Published As

Publication number Publication date
PL2146745T3 (pl) 2015-11-30
AU2008243049A1 (en) 2008-10-30
IL201440A0 (en) 2010-06-16
BRPI0810250A2 (pt) 2014-10-14
CY1116671T1 (el) 2017-03-15
HUE027584T2 (en) 2016-11-28
MY150525A (en) 2014-01-30
CN101687035B (zh) 2013-06-12
EP2146745A4 (en) 2011-11-30
PT2146745E (pt) 2015-10-14
WO2008130969A2 (en) 2008-10-30
US20110229475A1 (en) 2011-09-22
CR11116A (es) 2010-03-22
CA2684626C (en) 2014-11-04
KR101560841B1 (ko) 2015-11-11
JP5441885B2 (ja) 2014-03-12
HRP20150937T1 (hr) 2015-10-09
US8828384B2 (en) 2014-09-09
NZ580239A (en) 2012-07-27
DK2146745T3 (en) 2015-09-14
SI2146745T1 (sl) 2015-10-30
EA024621B1 (ru) 2016-10-31
CA2684626A1 (en) 2008-10-30
US8496932B2 (en) 2013-07-30
CL2008001071A1 (es) 2009-05-22
DOP2009000236A (es) 2009-11-15
MA31310B1 (fr) 2010-04-01
MX2009011153A (es) 2009-10-30
CN101687035A (zh) 2010-03-31
AU2008243049B2 (en) 2011-04-21
EP2146745A2 (en) 2010-01-27
BRPI0810250A8 (pt) 2017-02-21
HK1136970A1 (en) 2010-07-16
EP2146745B1 (en) 2015-06-17
US20140010807A1 (en) 2014-01-09
EA200970954A1 (ru) 2010-08-30
KR20100020946A (ko) 2010-02-23
TWI473815B (zh) 2015-02-21
US20080262203A1 (en) 2008-10-23
ES2547475T3 (es) 2015-10-06
TW200906855A (en) 2009-02-16
CO6251323A2 (es) 2011-02-21
IL201440A (en) 2016-08-31
WO2008130969A3 (en) 2008-12-18
JP2010524469A (ja) 2010-07-22

Similar Documents

Publication Publication Date Title
PE20090302A1 (es) Anticuerpo multiespecifico
CL2008002349A1 (es) Molecula de anticuerpo que se une a cd37 humano; molecula de adn que la codifica; vector de expresion y celula huesped; metodo para producir dicho anticuerpo; composicion farmaceutica que la comprende; método in vitro para suprimir células b que expresan cd37 en una población de células.
PE20061395A1 (es) Anticuerpos contra miostatina
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
PE20121361A1 (es) Antagonistas de pcsk9
PE20120205A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y citarabina
PE20121034A1 (es) Anticuerpos anti-factor d humanizados
PE20131412A1 (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
PE20140004A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y bortezomib
PE20141162A1 (es) Anticuerpos anti-il-23
PE20131413A1 (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
PE20180502A1 (es) Composiciones anti-cgrp y uso de las mismas
PE20140229A1 (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
AR065433A1 (es) Anticuerpos anti-cxcl13
AR074221A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y ciclofosfamida
AR078795A1 (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
PE20141546A1 (es) Anticuerpos anti-cd134(ox40) y sus usos de los mismos
AR060417A1 (es) Anticuerpos dirigidos contra receptor del activador de plasminogeno tipo uroquinasa (upar) y usos de dichos anticuerpos
GT201200058A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
PE20121531A1 (es) Inmunoglobulinas con dominio variable dual
CO6260105A2 (es) Anticuerpos humanos contra cd20 humano y metodo para utilizarlos
MX2013003592A (es) Anticuerpos contra la tweak humana y usos de los mismos.
PE20141166A1 (es) Anticuerpos anti-angptl3 y usos de los mismos
AR052889A1 (es) Anticuerpos contra interleuquina-1 beta
PE20141060A1 (es) Inmunoglobulinas de dominio variable dual biespecificas de il-1 alfa y beta y su uso

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed